Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 13 962 / https://doi.org/10.3332/ecancer.2019.962

Research

Evaluation of the expression of the oncogene C-ERBB-2/HER2 in advanced gastric cancer cases from Costa Rica

Justification: The prevalence of gastric cancer (GC) with increased expression of the HER2 oncoprotein shows important variations worldwide. Incidence and mortality rates of GC in Costa Rica are among the highest in Latin America and the world; however, the prevalence of HER2-positive cases in this country is unknown. Evaluation of this parameter is important to decide the therapeutic approach for GC patients. The aim of this study was to provide an estimation of the prevalence of GC patients overexpressing the HER2 oncogene in Costa Rica.

Methods: The investigation was carried out in two phases. The first one consisted of a retrospective review of 331 clinical records of patients diagnosed with advanced or metastatic GC from January 2010 to January 2012 in four hospitals in Costa Rica. In the second phase, immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) analyses were performed in formalin-fixed and paraffin-embedded (FFPE) surgical samples from 50 patients diagnosed with GC between 2012 and 2015.

Results: Of the 331 clinical files reviewed, the assessment of HER2 status was carried out in 62 patients (18.7%), of which only five (8%) were HER2-positive. In the 50 surgical specimens in which IHC and FISH analyses were performed, two of them (4%) presented overexpression and amplification of the HER2 oncogene.

Conclusion: This study suggests that the prevalence of GC cases overexpressing the HER2 oncogene in Costa Rica is less than 8%. This is the first attempt ever undertaken to estimate the prevalence of HER2-positivity in GC in Costa Rica.

Keywords: oncogene, gastric cancer (GC), immunohistochemistry (IHC), fluorescent in situ hybridisation (FISH), HER2

Loading Article Metrics ... Please wait

Related articles

Review: Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

Abstract | Full Article | PDF Published: 27 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1022

Clinical Study: Prospective study to assess the survival outcomes of planned irradiation of ipsilateral subventricular and periventricular zones in glioblastoma

Abstract | Full Article | PDF Published: 26 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1021

Research: Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population

Abstract | Full Article | PDF | Español Published: 24 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1020

Clinical Study: Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer

Abstract | Full Article | PDF Published: 09 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1019

Research: Cancer care in times of conflict: cross border care in Pakistan of patients from Afghanistan

Abstract | Full Article | PDF Published: 05 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1018



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation